Correction: Analysis of mortality risk and influencing factors in female patients with young-onset type 2 diabetes - Summary - MDSpire

Correction: Analysis of mortality risk and influencing factors in female patients with young-onset type 2 diabetes

  • By

  • Ling Xiang

  • Mingmin Zhu

  • Zi Yan

  • Zhijin Geng

  • Yuankai Zhou

  • Zhongming Sun

  • Dandan Miao

  • Yong Zhang

  • Jinyi Zhou

  • Enchun Pan

  • Wen Hu

  • July 2, 2026

  • 0 min

Share

Objective:

To correct author affiliations in the analysis of mortality risk and influencing factors in female patients with young-onset type 2 diabetes.

Approach:
  • Author Affiliation Correction: The correction addresses the erroneous assignment of affiliations for author Jinyi Zhou and clarifies the correct affiliations.
Key Findings:
  • Author Jinyi Zhou's affiliation was corrected from 'Huai’an Center for Disease Control and Prevention' to 'Jiangsu Provincial Center for Disease Control and Prevention'.
  • The affiliation for 'The Affiliated Huai’an Hospital of Xuzhou Medical University/The Second People’s Hospital of Huai’an' was corrected from 'Department of Endocrinology, Huai’an Hospital' to the accurate institutions.
Interpretation:

The original article has been updated to reflect accurate author affiliations.

Conclusion:

The corrections ensure proper attribution of authorship and affiliations in the study.

Sources:

Original Source(s)

Correction: Analysis of mortality risk and influencing factors in female patients with young-onset type 2 diabetes

  • by Ling Xiang, Mingmin Zhu, Zi Yan, Zhijin Geng, Yuankai Zhou, Zhongming Sun, Dandan Miao, Yong Zhang, Jinyi Zhou, Enchun Pan, Wen Hu

  • July 2, 2026

Related Content

Clavicular Gorham-Stout disease: a rare case report and literature review

Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy

Development and validation of a prediction model for psychological distress in patients with differentiated thyroid cancer undergoing ¹³¹I therapy